Inflammatory bowel disease, often called IBD, is a long-term condition that causes ongoing inflammation in the digestive system. The two main types are Crohn’s disease and ulcerative colitis. People with these conditions often experience symptoms such as stomach pain, diarrhea, fatigue, and weight loss.
Over time, the constant inflammation can damage the lining of the intestine and lead to other health problems. One of the most serious complications is a higher risk of developing colorectal cancer, also known as colon cancer. Doctors have known about this increased cancer risk for many years, but the biological reasons behind it have not been fully understood.
A new study from scientists at Weill Cornell Medicine has now uncovered an important immune system process that may help explain why this happens. The research was published in the scientific journal Immunity and provides new insight into how chronic inflammation in the gut may create conditions that encourage cancer to grow.
The study focused on a protein called TL1A, which is part of the body’s immune signaling system. This protein helps immune cells communicate with each other when the body is fighting infection or dealing with inflammation.
Previous research had already linked TL1A to inflammatory bowel disease and colorectal cancer, but scientists did not fully understand how it contributed to these diseases. The new research shows that TL1A can trigger a chain reaction inside the immune system that ultimately promotes tumor development in the colon.
The researchers discovered that TL1A activates a special group of immune cells located in the gut. These cells are called innate lymphoid cells type 3, or ILC3s. Unlike some immune cells that circulate throughout the body, ILC3 cells live mainly in the lining of the intestine where they help control inflammation and defend against harmful microbes.
When TL1A activates these cells, they release a powerful chemical signal known as GM-CSF. This signal travels through the body and reaches the bone marrow, which is the soft tissue inside bones that produces blood cells. Once the signal arrives in the bone marrow, it stimulates the rapid production of neutrophils.
Neutrophils are a type of white blood cell that normally play an important role in fighting infections. They are among the first immune cells to arrive at sites of injury or inflammation. However, the new study suggests that in the case of inflammatory bowel disease, large numbers of neutrophils may actually create a harmful environment in the gut.
The researchers describe this rapid increase in neutrophil production as “emergency granulopoiesis,” a process the body uses when it needs to quickly produce immune cells during serious infection or inflammation. In people with IBD, signals from the inflamed gut appear to trigger this process even when there is no infection present.
After being produced in the bone marrow, the neutrophils travel through the bloodstream and gather in the intestine. Once there, they release reactive molecules and inflammatory chemicals that can damage the cells lining the colon. This damage can lead to changes in DNA, which increases the chance that normal cells will transform into cancer cells.
The scientists also found that the neutrophils recruited through this pathway showed a unique pattern of gene activity. Many of the activated genes were linked to cancer growth and tumor progression. This same pattern of gene activity was also observed in colon tissue samples taken from patients with IBD.
Interestingly, the tumor-promoting pattern was less noticeable in patients who had received experimental treatments designed to block the TL1A protein. This finding suggests that therapies targeting TL1A may not only reduce inflammation in IBD but could also lower the risk of colorectal cancer.
The research team believes this discovery could open new possibilities for both diagnosis and treatment. Doctors may eventually be able to monitor the activity of this immune pathway to identify patients who are at the greatest risk of developing colon cancer.
At the same time, drugs that block parts of this chain reaction may help prevent tumors from forming. The study’s senior author, Dr. Randy Longman, who directs the Jill Roberts Center for Inflammatory Bowel Disease at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, explained that understanding this immune system process is an important step forward.
He noted that doctors currently have limited tools for reducing the cancer risk associated with inflammatory bowel disease. The study’s first author, Dr. Sílvia Pires, added that the findings reveal a larger system connecting the gut and the bone marrow. This system allows signals from the inflamed intestine to influence how immune cells are produced throughout the body.
Understanding this communication network may help researchers develop more personalized treatments for people living with IBD. Although the findings are promising, the study was mainly conducted in laboratory models and early biological studies. More research will be needed to confirm how the same processes work in large groups of patients.
Future studies will also investigate whether repeated exposure to GM-CSF signals might gradually change bone marrow cells in ways that increase the likelihood of inflammatory bowel disease itself. If scientists can better understand these early immune changes, it may become possible to detect or even prevent the disease before serious damage occurs.
Overall, the research highlights how deeply connected different parts of the immune system are. It shows that inflammation in the gut can influence the bone marrow and reshape the behavior of immune cells throughout the body.
By uncovering this chain reaction, scientists have taken an important step toward understanding why people with inflammatory bowel disease face such a high risk of colorectal cancer.
The findings also point toward new strategies that may help doctors detect cancer risk earlier and develop treatments that protect patients from one of the most serious complications of IBD.
If you care about cancer, please read studies that low-carb diet could increase overall cancer risk, and new way to increase the longevity of cancer survivors.
For more health information, please see recent studies about how to fight cancer with these anti-cancer superfoods, and results showing daily vitamin D3 supplementation may reduce cancer death risk.
Copyright © 2026 Knowridge Science Report. All rights reserved.
